FindTrial
Sign In

SCH 727965

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Breast NeoplasmsCarcinoma, Non-Small-Cell LungLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphocytic, Chronic. B-CellLeukemia, Myeloid, AcuteLymphoblastic Leukemia, AcuteLymphoma, Mantle-CellLymphoma, Non-Hodgkin

Phase 1

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
CompletedNCT00871910
Merck Sharp & Dohme LLCLymphoma, Non-Hodgkin, Multiple Myeloma, Solid Tumors
Start: 2006-10-11End: 2010-02-22Updated: 2017-10-23
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
CompletedNCT00871663
Merck Sharp & Dohme LLCLeukemia, Lymphocytic, Chronic. B-Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma +1
Start: 2006-08-31End: 2012-10-31Updated: 2015-04-20

Phase 2

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
CompletedNCT00732810
Merck Sharp & Dohme LLCBreast Neoplasms, Carcinoma, Non-Small-Cell Lung
Start: 2008-07-31End: 2011-06-30Updated: 2015-08-05
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
TerminatedNCT00798213
Merck Sharp & Dohme LLCLeukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute
Start: 2009-01-31End: 2010-04-30Updated: 2015-02-04
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
TerminatedNCT00871546
Merck Sharp & Dohme LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Start: 2009-03-31End: 2010-12-31Updated: 2015-08-07

Related Papers

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
2013-10-16105 citations